Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02203136 · ClinicalTrials.gov registry record
Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 16
- Enrollment target
NCT02203136: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT02203136 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02203136 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The goal of this research study is to improve detection of cancer outside of the bladder through genetic testing and improved imaging.
Primary Outcome
Improved cross sectional imaging with pelvic MRI, and biopsy specimen molecular profiling used to identify muscle invasive bladder cancer (noc-MIBC). Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC.
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Tissue Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-06-25 |
| Est. Completion | 2019-05-16 |
What the finished NCT02203136 record still lists
NCT02203136 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT02203136 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02203136 about?
NCT02203136 is a clinical study titled "Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging". The goal of this research study is to improve detection of cancer outside of the bladder through genetic testing and improved imaging.
What is the current status of trial NCT02203136?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2014-06-25. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT02203136?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Tissue Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02203136?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI